Aquestive Therapeutics Inc (AQST) saw an uptrend of 1209294% in the recent trading with $1510000.0 being its most recent. The current price level -43.97% lower than the highest price of $5.80 marked by the stock while trading over the past 52-weeks, whereas it is 53.30% higher than the lowest price of $2.12 the company dropped to over past 52-weeks. The latest news story on AQST appeared in (GlobeNewswire) under the title “Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit” on Today.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.11 for the stock.
Aquestive Therapeutics Inc Earnings – What Happened With AQST
Coming around sales and income figures on AQST Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Aquestive Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 99.32 million. AQST does have institutional investors; and they hold 42.63% of the stock.
As on 2024-06-30, BRATTON CAPITAL MANAGEMENT, L.P. was the top most holder in Aquestive Therapeutics Inc (NASDAQ:AQST) with an ownership of 9.81 million shares of the company or 10.7918 of the stake worth $25.51 million. The filing also reveals VR ADVISER, LLC as the second largest holder in the company with a control over 6.1109 of the outstanding shares. Its stake is worth $14.44 million for having 5.56 million shares in hand.
BLACKROCK INC. also came holding a key position in the company during the recent quarter and it now holds 6 of the outstanding shares. With this there are now 160.0 institutions which have possession in AQST’s shares.
Key Metrics forAQST
Technical Analysis of Aquestive Therapeutics Inc (NASDAQ:AQST) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Aquestive Therapeutics Inc (AQST), we notice that the stock’s 20-day average volume is at 1,604,570 shares. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 1,549,116 shares. And to end with, AQST’s 100-day average volume are 1,628,154 shares.
